{"id":"W4206960604","doi":"","title":"KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema.","year":2022,"lang":"en","type":"article","venue":"Bern Open Repository and Information System (University of Bern)","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Aflibercept; Medicine; Dosing; Clinical endpoint; Diabetic retinopathy; Adverse effect; Visual acuity; Macular edema; Randomized controlled trial; Ophthalmology; Surgery; Internal medicine; Diabetes mellitus; Chemotherapy; Bevacizumab; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004717313,0.0001063251,0.0005576361,0.00009581423,0.000356083,0.00004036191,0.0001248065,0.00004030058,0.00002511639],"category_scores_gemma":[0.00002677987,0.000108262,0.0001382002,0.00008060758,0.00005938905,0.0007757482,0.0001940037,0.00005106801,0.000001773391],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007012426,"about_ca_system_score_gemma":0.00008732808,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001787341,"about_ca_topic_score_gemma":0.000002822164,"domain_scores_codex":[0.9988065,0.0001366597,0.0005514335,0.0001556584,0.000253344,0.00009641697],"domain_scores_gemma":[0.9986017,0.0001331963,0.0008143404,0.0002079816,0.0001212607,0.0001215303],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5191072,0.006921425,0.1143706,0.01554295,0.01510436,0.001301334,0.1147241,0.0008584834,0.01744497,0.01244803,0.01488235,0.1672942],"study_design_scores_gemma":[0.504229,0.01446508,0.1879435,0.003392427,0.009844901,0.0009019737,0.1940813,0.03352772,0.005140869,0.0001400235,0.04494544,0.001387747],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919792,0.0002194064,0.0002361221,0.00008729266,0.0001014288,0.001293873,0.001669047,0.00001398208,0.004399693],"genre_scores_gemma":[0.9979771,0.00002027424,0.0003771711,0.00001792505,0.0000224552,0.000005578775,0.000673537,0.000004821841,0.0009011248],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1659064,"threshold_uncertainty_score":0.4414795,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02779509310067557,"score_gpt":0.2721787307493523,"score_spread":0.2443836376486767,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}